Other studies have found treatments with dipeptidyl peptidase-4 (DPP4) inhibitors resulted in a significant increase in urinary cAMP in T2D patients and rat models of insulin-deficiency suggesting a direct impact of the incretin system activity and urinary cAMP levels50, 53. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.